{"id":79922,"date":"2026-06-09T07:22:15","date_gmt":"2026-06-09T07:22:15","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/79922\/"},"modified":"2026-06-09T07:22:15","modified_gmt":"2026-06-09T07:22:15","slug":"roche-collaborates-with-nurix-therapeutics-in-2-billion-blood-cancer-drug-deal-etpharma","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/79922\/","title":{"rendered":"Roche Collaborates with Nurix Therapeutics in $2 Billion Blood Cancer Drug Deal, ETPharma"},"content":{"rendered":"<p>                                        <img fetchpriority=\"high\" decoding=\"async\" width=\"590\" height=\"442\" class=\"unveil\" loading=\"eager\" style=\"width:100%;max-height:100%\" src=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/06\/131604221.cms.jpeg\" captionrendered=\"1\" alt=\"\"\/>Zurich: Swiss pharmaceutical giant Roche has entered an exclusive licensing and collaboration agreement with <a id=\"36125283\" type=\"Denny\" weightage=\"20\" keywordseo=\"Nurix-Therapeutics\" source=\"keywords\" meta.keywordsubtype=\"org\" meta.entityname=\"Nurix Therapeutics\" meta.hostid=\"266\" class=\"news-keywords\" href=\"https:\/\/pharma.economictimes.indiatimes.com\/tag\/nurix+therapeutics\" rel=\"nofollow noopener\" target=\"_blank\">Nurix Therapeutics<\/a> of up to $2.3 billion, the company said on Monday.<\/p>\n<p>The deal focuses \u200con blood \u2060cancer \u2060drug <a id=\"36808186\" type=\"Denny\" weightage=\"20\" keywordseo=\"bexobrutideg\" source=\"keywords\" class=\"news-keywords\" href=\"https:\/\/pharma.economictimes.indiatimes.com\/tag\/bexobrutideg\" rel=\"nofollow noopener\" target=\"_blank\">bexobrutideg<\/a>, which degrades targeted proteins and is planned to enter a phase III clinical trial initiation for <a id=\"36808188\" type=\"Denny\" weightage=\"20\" keywordseo=\"chronic-lymphocytic-leukaemia\" source=\"keywords\" class=\"news-keywords\" href=\"https:\/\/pharma.economictimes.indiatimes.com\/tag\/chronic+lymphocytic+leukaemia\" rel=\"nofollow noopener\" target=\"_blank\">chronic lymphocytic leukaemia<\/a> (CLL) in the summer<\/p>\n<p>Nurix will receive $700 \u200bmillion upfront, with possible payouts \u2060for development, \u200cregulatory and sales milestones<\/p>\n<p>&#8220;We \u200bbelieve \u200bbexobrutideg could represent a \u2060major leap forward in the fight against complex \u200bblood cancers and other diseases,&#8221; Levi \u200bGarraway, Roche chief medical officer and head of global product development said<\/p>\n<p>The deal is expected to close in the third quarter \u200cof 2026<\/p>\n<p>Development costs for the drug will be \u200bcovered 60% \u200bby Roche and \u206040% by Nurix<\/p>\n<p>The companies will co-commercialise the drug in the United States, where \u200bthey will split the profits and losses equally, while Roche will commercialise outside of the U.S., paying Nurix royalties<\/p>\n<p>(Reporting by Marleen Kaesebier and Oliver Hirt, Editing by Friederike Heine)\n                                                                    <\/p>\n<p>                                    Published On Jun 9, 2026 at 12:25 PM IST<\/p>\n<p>\n                Join the community of 2M+ industry professionals.<br \/>\n                Subscribe to Newsletter to get latest insights &amp; analysis in your inbox.\n            <\/p>\n<p>                    All about ETPharma industry right on your smartphone! <\/p>\n<p>                        <img decoding=\"async\" loading=\"lazy\" width=\"90\" height=\"90\" src=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/06\/pharma_barcode.png\" alt=\"\"\/>                        <\/p>\n","protected":false},"excerpt":{"rendered":"Zurich: Swiss pharmaceutical giant Roche has entered an exclusive licensing and collaboration agreement with Nurix Therapeutics of up&hellip;\n","protected":false},"author":2,"featured_media":79923,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[41223,41320,41221,134,41462,41463],"class_list":["post-79922","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-bexobrutideg","tag-chronic-lymphocytic-leukaemia","tag-nurix-therapeutics","tag-roche","tag-roche-cancer-drug-agreement","tag-roche-pharmaceutical-news"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116718950680784795","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/79922","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=79922"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/79922\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/79923"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=79922"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=79922"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=79922"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}